Drugs / TCB008
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06463327 | Jan 2025 → Jun 2026 overdue | acute myeloid leukemia, myelodysplastic syndrome | TC Biopharm | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00588913 | Jan 2006 → Mar 2009 | kidney cancer, metastatic malignant neoplasm | Tokyo Women's Medical University | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05358808 | Aug 2022 → Jul 2025 | acute myeloid leukemia, myelodysplastic syndrome | TC Biopharm | Terminated | No outcome recorded |
| Phase 2 | NCT04834128 | Dec 2021 → Apr 2022 | COVID-19 | TC Biopharm | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCB008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04834128 ↗ |
| Known as | Gamma Delta T cells | “Patients then receive the expanded Gamma Delta T cells, aldesleukin, and zoledronic acid once a month for 6 months.” NCT00588913 ↗ |
| Modality | Cell therapy | “cellular adoptive immunotherapy uses a person's white blood cells that are treated in the laboratory” NCT00588913 ↗ |
| Route | Intravenous | “administration of gamma delta T cells by IV bolus injection” NCT04834128 ↗ |